Overview
Employees
1-10
Total raised
$43M
Founded date
2017
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 9, 2019 | Term Sheet — Wednesday, January 9 | AN IPO FREEZE Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop We were supposed to kick off 2019 with a wave of IPOs, including some of the biggest tech offerings we’ve seen in years. W... |
| Jan 8, 2019 | Stelexis Therapeutics Closes $43 million Series A | Stelexis Therapeutics, LLC announced that it closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells. Deerfield established Stelexis in 2017 together with scient... |
| Jan 8, 2019 | Daily funding roundup - January 8th, 2019 | LendingFront raised $4M; Headset raised $12.1M; Managed by Q raised $25M; Humatics raised $28M Carson Living: Carson is a real estate tech startup that provides services to unstaffed residential buildings. Carson has raised $3 million in se... |
| Jan 8, 2019 | Stelexis Therapeutics Closes $43M Series A | NEW YORK, NY, Stelexis Therapeutics announced that it closed a $43 million Series A financing today. >> Click here for more funding data on Stelexis Therapeutics >> To export Stelexis Therapeutics funding data to PDF and Exc... |
| Jan 7, 2019 | Stelexis Therapeutics Closes $43 million Series A | Stelexis Therapeutics, LLC announced that it closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells. Deerfield established Stelexis in 2017 together with scient... |
| Jan 7, 2019 | Stelexis Therapeutics Closes $43M in Series A Funding | Stelexis Therapeutics, a NYC-based cancer therapeutics company, closed a $43m Series A financing. Deerfield established Stelexis in 2017 together with scientific founders, Ulrich Steidl, Evripidis Gavathiotis, Amit Verma, and Roman Perez-So... |
Reviews 0
FAQ about Targeting the
When was Targeting the founded?
Targeting the was founded in 2017.
How much funding has Targeting the raised?
Targeting the has raised $43M in total across 1 funding round.
What has the press written about Targeting the?
Parsers VC has collected 7 articles mentioning Targeting the, among them “Term Sheet — Wednesday, January 9” (Jan 9, 2019) and “Stelexis Therapeutics Closes $43 million Series A” (Jan 8, 2019).
Is Targeting the still active?
Yes, Targeting the is active; its latest activity on Parsers VC dates from Nov 10, 2021.